January 2022 - Volume 81 - 1

EDITORIALS

1. Greetings from the editor 2022 

2. Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment 

3. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one ? 

REVIEW

4. Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning 

VIEWPOINT

5. From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? 

RECOMMENDATIONS

6. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis 

7. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 

RHEUMATOID ARTHRITIS

8. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register 

9. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis 

10. Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy 

PSORIATIC ARTHRITIS

11. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis 

12. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis 

13. Does biologic therapy impact the development of PsA among patients with psoriasis? 

OSTEOARTHRITIS

14. METTL3-mediated m6A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression

SYSTEMIC LUPUS ERYTHEMATOSUS

SYSTEMIC SCLEROSIS

16. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease 

VASCULITIS

17. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study 

18. Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis

EPIDEMIOLOGY

19. Native joint infections in Iceland 2003–2017: an increase in postarthroscopic infections 

LETTERS

20. Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA 

21. B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics 

22. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases 

ELECTRONIC PAGES

23. Correspondence on ‘Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor’ by Ishikawa et al 

24. Response to: ‘Corresponence on ‘Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor’ by Ishikawa et al’ by Regueiro and Gonzalez

25. Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study 

26. Response to: ‘Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study’ by Lee 

27. Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells 

28. Response to: ‘Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells’ by Raychaudhuri et al 

29. Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years 

30. Response to: ‘Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years’ by Parperis

31. Correspondence on: ‘Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?’ by Wallman et al 

32. Response to: ‘Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?’ by Proft et al.

33. Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 

34. Response to: ‘Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease’ by Campochiaro et al 

35. Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation’ by Braaten et al 

36. Response to: Correspondence on “Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation” by Braaten et al 

37. Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers? 

38. Response to: ‘Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?’ by Fayand et al 

39. Correction: Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis

ISSUE INFORMATION